Lv1
26 积分 2025-07-10 加入
Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial
3个月前
已完结
Dysregulation of cholesterol metabolism in cancer progression
4个月前
已完结
Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities
4个月前
已完结
Mechanisms and regulation of cholesterol homeostasis
4个月前
已完结
Targeting cholesterol metabolism: a promising therapy strategy for cancer
4个月前
已完结
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial
5个月前
已完结
Glycogen drives tumour initiation and progression in lung adenocarcinoma
5个月前
已完结
Benmelstobart Ups ES-SCLC Survival
5个月前
已完结
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition
7个月前
已完结
Publisher Correction: NeuroD1 drives a KAT2A-FDFT1 signaling axis to promote cholesterol biosynthesis and hepatocellular carcinoma progression via histone H3K27 acetylation
9个月前
已完结
皖公网安备34019202002308
